良心藥廠
默克藥廠廢棄了兩款開發中V590和V591的冠狀病毒疫苗,並説經過廣泛研究，得出的結論是，注射疫苗所得到的保護作用比本身自然感染病毒而發展出來的抗體,產生“較差”的免疫系統反應。
該公司申明，它將專注於標韱為MK-7110和MK-4482的治療藥物研究作為代替。
Merck Scraps COVID Vaccines; Says It’s More Effective To Get The Virus And Recover
Shots generated an ‘inferior’ immune system response in comparison with natural infection
26 January, 2021
The company announced that the shots V590 and V591 were ‘well tolerated’ by test patients, however they generated an ‘inferior’ immune system response in comparison with natural infection.
The company stated that instead it will focus on research into therapeutic drugs labeled as MK-7110 and MK-4482.
The drugs aim to protect patients from the damage of an overactive immune response to the virus.
“Interim results from a Phase 3 study showed a greater than 50 percent reduction in the risk of death or respiratory failure in patients hospitalized with moderate to severe COVID-19,” the company’s statement noted of the MK-7110 drug.
Merck is to receive around $356 million from the US government to fast-track production of the potential treatments under Operation Warp Speed.
Chief Marketing Officer Michael Nally recently told Bloomberg that Merck is aiming to produce some 20 million courses of the MK-4482 drug, an oral antiviral which patients will take twice a day for five days.
more:
沒有留言:
發佈留言